Just a few short years ago, the nation learned about 4,000 beagles rescued from a breeding facility in Virginia run by a company called Invigo. They had been warehoused in filth and deprivation, destined for painful drug experiments. Their story shocked the conscience — and spurred a movement.

That movement has just reached a historic turning point. The U.S. government has finally taken decisive steps to shed its decades-old dependence on animal testing.

Cruelty-free science

After years of advocacy, Congress, federal agencies, industry leaders, and scientists are finally aligned in a shared vision: a future of human-relevant, cruelty-free science. Animal testing has never been just inhumane — it has been scientifically inadequate, expensive, and dangerously misleading.

On April 29, the National Institutes of Health (NIH) — the largest public funder of medical research in the world — announced that it will prioritize human-based research methods over outdated and unreliable animal testing. Just weeks earlier, the U.S. Food and Drug Administration (FDA) unveiled a plan to phase out animal use in drug testing altogether, starting with a certain class of immunotherapy drugs known as monoclonal antibodies.

Advertise with us

These are seismic shifts in how America approaches science and medicine. The catalyst for this progress was the FDA Modernization Act 2.0, signed into law at the end of 2022 with unanimous, bipartisan support. It had been introduced by Republican senator Rand Paul, a libertarian, and co-sponsored by socialist senator Bernie Sanders, a socialist. That law eliminated a nearly century-old federal mandate requiring animal tests for every new drug — even though 90 to 95% of drugs that pass those tests ultimately fail in human trials.

We’ve known for decades that mice aren’t miniature humans, and that using beagles and primates as proxies for our complex biology is both ethically fraught and medically flawed. What we needed was the political will and public leadership to pivot to better science.

Under the leadership of newly appointed FDA commissioner Marty Makary and NIH director Jay Bhattacharya, the United States is now moving aggressively to implement human-centered research strategies. NIH is establishing a new Office of Research Innovation, Validation, and Application to drive the adoption and integration of cutting-edge technologies like organ-on-a-chip systems, 3D bioprinting, and AI-based predictive models — all of which offer greater accuracy and reliability in testing new drugs and treatments.

Transforming research

These innovations aren’t theoretical. They are already transforming biomedical research, from modeling rare diseases like Fragile-X syndrome and NGLY1 deficiency, to developing personalized cancer therapies. They are especially vital in fields like immunotherapy and gene editing, where animal models simply don’t work.

Last month’s announcements from NIH, FDA, and even the Environmental Protection Agency — which reaffirmed its commitment to end animal testing for chemical safety screening — collectively signal a “bloodless revolution” in public health, as Animal Wellness Action aptly described it.

Advertise with us

The stakes are enormous. NIH spends nearly half of its $45 billion annual budget on animal research. The FDA’s outdated methods have slowed the development of life-saving drugs. By embracing modern science, we can unlock treatments faster, spend taxpayer money more efficiently, and spare millions of animals from lives of suffering.

This transformation will not happen overnight. But the commitment is real — and it is bipartisan. Legislation like the FDA Modernization Act 3.0, now pending in Congress, aims to ensure full and vigorous implementation of the reforms already signed into law. It has broad support from Republicans and Democrats, from scientists and patient advocates, from animal welfare groups and biotech companies.

Pennsylvania is helping to lead the way. For example, Biotech innovators like Vivodyne — which cultivates human tissue to replace animal models — are headquartered in the state. Ten of the 17 members of the state’s congressional delegation supported the original FDA Modernization Act, recognizing both the moral urgency and the scientific opportunity this moment represents.

A paradigm shift

And for those beagles rescued from Envigo? (The company was fined $35.5 million.) Their suffering wasn’t in vain. Their story helped awaken a nation. And their legacy is now woven into a broader movement that promises to bring us safer drugs, stronger science, and a more compassionate society.

We are witnessing a paradigm shift — not just in how we treat animals, but in how we define progress itself. The era of animal testing is coming to an end. April 2025 was the beginning of that end, especially if Congress passes the FDA Modernization Act 3.0 — and the dawn of a smarter, kinder future.

Natalie Ahwesh is executive director of Humane Action Pittsburgh and director of state affairs for Animal Wellness Action. Her previous article was “The government's 'milk mandate' is not good for all our children.”